증권사 리포트&코멘트
https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/
Elevar Therapeutics
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option - Elevar Therapeutics
Lyrfigtu demonstrated a confirmed ORR of 46% and mDOR of 11.8 months, with a predictable and manageable safety profile CCA, also known as bile duct cancer, is diagnosed in about 8,000 people in the U.S. each year FORT LEE, N.J., Sept. 23 – Elevar Therapeutics, […]
외부 자료를 정리한 참고자료이며 투자 권유가 아닙니다. 기사·리포트의 저작권은 원저작자에게 있습니다. · 게시중단 요청